<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067166</url>
  </required_header>
  <id_info>
    <org_study_id>Ansuvimab EAP-2020-DRC</org_study_id>
    <nct_id>NCT05067166</nct_id>
  </id_info>
  <brief_title>Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP</brief_title>
  <official_title>Open-Label, Expanded Access Protocol of a Human Monoclonal Antibody, Ansuvimab (mAb114), Administered as an Investigational Therapeutic to Ebola-Infected Patients or as a High-Risk Ebola Post-Expo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ridgeback Biotherapeutics, LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ridgeback Biotherapeutics, LP</source>
  <brief_summary>
    <textblock>
      The human monoclonal antibody (mAb), ansuvimab (mAb114), will be provided to Ebola-infected&#xD;
      patients as either a treatment or as PEP under expanded access. Ansuvimab is administered at&#xD;
      50 mg/kg as a single intravenous (IV) infusion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, intermediate size patient population, expanded access protocol (EAP)&#xD;
      of the ansuvimab investigational product administered once by IV infusion at a dose of about&#xD;
      50 mg/kg (weight-based dosing). Assessment of safety will include clinical observation and&#xD;
      monitoring following administration. Patients will be monitored and assessed daily through&#xD;
      discharge for safety and the incidence of serious adverse events (SAEs) and AEs that by&#xD;
      clinical judgement are atypical for EVD, and any AEs that occur during product infusions.&#xD;
      Blood will be collected for ansuvimab PK assessment, sGP quantification and RT-PCR evaluation&#xD;
      of viral load by available assay. A blood sample for Ebolavirus viral load measurement is&#xD;
      collected before mAb114 administration and at subsequent study timepoints per the Schedule of&#xD;
      Evaluations. Subjects will be followed for up to 3 weeks after the product administration or&#xD;
      until discharge from the Ebola Treatment Unit (ETU), whichever is later. Survival status for&#xD;
      infected patients and/or EVD disease status for PEP subjects will be recorded as applicable.&#xD;
      Ansuvimab will be provided for expanded access in the DRC and can be used in any DRC&#xD;
      Ebolavirus (Zaire) outbreak location as authorized by the DRC Ministry of Health and the&#xD;
      local Institutional Review Board.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Hemorrhagic Fever, Ebola</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ansuvimab</intervention_name>
    <description>single infusion 50 mg/kg IV</description>
    <other_name>mAb114, Ebanga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female with laboratory confirmed (based on local standard of care) EBOV&#xD;
             infection or with recent high-risk EBOV exposure as determined by a treating Physician&#xD;
             or designee.&#xD;
&#xD;
          -  Able to provide proof of identity to the satisfaction of the clinical team&#xD;
&#xD;
          -  Able and willing to complete the informed consent process personally, or if the&#xD;
             patient is unable to do so, then informed consent completed by a legally-authorized&#xD;
             representative according to local laws and regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Any medical condition that, in the opinion of the Treating Physician, would place the&#xD;
        patient at an unreasonably increased risk through participation in this treatment protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jean Jacques Muyembe-Tamfum, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INRB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut National de Recherche Biomedical</name>
      <address>
        <city>Beni</city>
        <state>North Kivu</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut National de Recherche Biomédicale</name>
      <address>
        <city>Butembo</city>
        <state>North Kivu</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sierra Leone Teaching Hospital Complex</name>
      <address>
        <city>Freetown</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
    <country>Sierra Leone</country>
  </location_countries>
  <link>
    <url>http://www.ridgebackbio.com</url>
    <description>Ridgeback Biotherapeutics (corporate website)</description>
  </link>
  <link>
    <url>https://www.inrb.net</url>
    <description>Institut National pour la Recherche Biomedicale</description>
  </link>
  <link>
    <url>https://apps.who.int/iris/handle/10665/250580</url>
    <description>WHO: Guidance for managing ethical issues in infectious disease outbreaks</description>
  </link>
  <link>
    <url>https://www.who.int/emergencies/ebola/MEURI-Ebola.pdf</url>
    <description>WHO: Notes for the record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions for Ebola Virus Disease (EVD)</description>
  </link>
  <reference>
    <citation>Bebell LM, Riley LE. Ebola virus disease and Marburg disease in pregnancy: a review and management considerations for filovirus infection. Obstet Gynecol. 2015 Jun;125(6):1293-1298. doi: 10.1097/AOG.0000000000000853. Review.</citation>
    <PMID>26000499</PMID>
  </reference>
  <reference>
    <citation>Broadhurst MJ, Brooks TJ, Pollock NR. Diagnosis of Ebola Virus Disease: Past, Present, and Future. Clin Microbiol Rev. 2016 Oct;29(4):773-93. doi: 10.1128/CMR.00003-16. Review.</citation>
    <PMID>27413095</PMID>
  </reference>
  <reference>
    <citation>Chérif MS, Koonrungsesomboon N, Kassé D, Cissé SD, Diallo SB, Chérif F, Camara F, Koné A, Avenido EF, Diakité M, Diallo MP, Le Gall E, Cissé M, Karbwang J, Hirayama K. Ebola virus disease in children during the 2014-2015 epidemic in Guinea: a nationwide cohort study. Eur J Pediatr. 2017 Jun;176(6):791-796. doi: 10.1007/s00431-017-2914-z. Epub 2017 Apr 25.</citation>
    <PMID>28444452</PMID>
  </reference>
  <reference>
    <citation>Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016 Mar 18;351(6279):1339-42. doi: 10.1126/science.aad5224. Epub 2016 Feb 25.</citation>
    <PMID>26917593</PMID>
  </reference>
  <reference>
    <citation>Fischer WA 2nd, Vetter P, Bausch DG, Burgess T, Davey RT Jr, Fowler R, Hayden FG, Jahrling PB, Kalil AC, Mayers DL, Mehta AK, Uyeki TM, Jacobs M. Ebola virus disease: an update on post-exposure prophylaxis. Lancet Infect Dis. 2018 Jun;18(6):e183-e192. doi: 10.1016/S1473-3099(17)30677-1. Epub 2017 Nov 15. Review.</citation>
    <PMID>29153266</PMID>
  </reference>
  <reference>
    <citation>Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. doi: 10.1016/S0140-6736(19)30036-4. Epub 2019 Jan 24. Erratum in: Lancet. 2020 May 30;395(10238):1694.</citation>
    <PMID>30686586</PMID>
  </reference>
  <reference>
    <citation>Jacobs M, Aarons E, Bhagani S, Buchanan R, Cropley I, Hopkins S, Lester R, Martin D, Marshall N, Mepham S, Warren S, Rodger A. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis. 2015 Nov;15(11):1300-4. doi: 10.1016/S1473-3099(15)00228-5. Epub 2015 Aug 25.</citation>
    <PMID>26321189</PMID>
  </reference>
  <reference>
    <citation>Mbala-Kingebeni P, Aziza A, Di Paola N, Wiley MR, Makiala-Mandanda S, Caviness K, Pratt CB, Ladner JT, Kugelman JR, Prieto K, Chitty JA, Larson PA, Beitzel B, Ayouba A, Vidal N, Karhemere S, Diop M, Diagne MM, Faye M, Faye O, Aruna A, Nsio J, Mulangu F, Mukadi D, Mukadi P, Kombe J, Mulumba A, Villabona-Arenas CJ, Pukuta E, Gonzalez J, Bartlett ML, Sozhamannan S, Gross SM, Schroth GP, Tim R, Zhao JJ, Kuhn JH, Diallo B, Yao M, Fall IS, Ndjoloko B, Mossoko M, Lacroix A, Delaporte E, Sanchez-Lockhart M, Sall AA, Muyembe-Tamfum JJ, Peeters M, Palacios G, Ahuka-Mundeke S. Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. Lancet Infect Dis. 2019 Jun;19(6):648-657. doi: 10.1016/S1473-3099(19)30118-5. Epub 2019 Apr 15.</citation>
    <PMID>31000464</PMID>
  </reference>
  <reference>
    <citation>Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 2016 Mar 18;351(6279):1343-6. doi: 10.1126/science.aad6117. Epub 2016 Feb 25.</citation>
    <PMID>26917592</PMID>
  </reference>
  <reference>
    <citation>Moekotte AL, Huson MA, van der Ende AJ, Agnandji ST, Huizenga E, Goorhuis A, Grobusch MP. Monoclonal antibodies for the treatment of Ebola virus disease. Expert Opin Investig Drugs. 2016 Nov;25(11):1325-1335. doi: 10.1080/13543784.2016.1240785. Epub 2016 Oct 8. Review.</citation>
    <PMID>27676206</PMID>
  </reference>
  <reference>
    <citation>Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol. 2003 Sep;77(18):9733-7. Review.</citation>
    <PMID>12941881</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zaire ebolavirus, EVD, EBANGA, compassionate use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

